Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Monolithic Power Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.3 (market cap $29.60B), while Monolithic Power Systems Inc trades at $1,418.27 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MPWR | |
|---|---|---|
Market Cap | $29.60B | $68.90B |
Sector | Health | Utilities |
52-Week High | $491.22 | $1.69K |
52-Week Low | $205.48 | $820.74 |
Enterprise Value | $27.56B | $67.51B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
MPWR trades at $1,425.01, up 3.18% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, supported by AI-driven revenue growth. Recent news highlights legal scrutiny but also analyst optimism post-Q2 results.
Outlook is positive with an 88% buy rating from analysts and a $1,870 consensus price target, though high valuation ratios and competitive risks warrant caution. Upside hinges on continued AI infrastructure demand, while downside risks include execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
